<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">EEG</journal-id>
<journal-id journal-id-type="hwp">speeg</journal-id>
<journal-title>Clinical EEG and Neuroscience</journal-title>
<issn pub-type="ppub">1550-0594</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1550059412459330</article-id>
<article-id pub-id-type="publisher-id">10.1177_1550059412459330</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Non-Convulsive Status Epilepticus Associated With Glutamic Acid Decarboxylase Antibody</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Çıkrıkçılı</surname>
<given-names>Uğur</given-names>
</name>
<xref ref-type="aff" rid="aff1-1550059412459330">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ulusoy</surname>
<given-names>Canan</given-names>
</name>
<xref ref-type="aff" rid="aff2-1550059412459330">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Turan</surname>
<given-names>Selin</given-names>
</name>
<xref ref-type="aff" rid="aff2-1550059412459330">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yıldız</surname>
<given-names>Şenay</given-names>
</name>
<xref ref-type="aff" rid="aff1-1550059412459330">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bilgiç</surname>
<given-names>Başar</given-names>
</name>
<xref ref-type="aff" rid="aff1-1550059412459330">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hanağası</surname>
<given-names>Haşmet</given-names>
</name>
<xref ref-type="aff" rid="aff1-1550059412459330">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Baykan</surname>
<given-names>Betül</given-names>
</name>
<xref ref-type="aff" rid="aff1-1550059412459330">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Tüzün</surname>
<given-names>Erdem</given-names>
</name>
<xref ref-type="aff" rid="aff1-1550059412459330">1</xref>
<xref ref-type="aff" rid="aff2-1550059412459330">2</xref>
<xref ref-type="corresp" rid="corresp1-1550059412459330"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gürvit</surname>
<given-names>Hakan</given-names>
</name>
<xref ref-type="aff" rid="aff1-1550059412459330">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-1550059412459330"><label>1</label>Istanbul University, Istanbul Faculty of Medicine, Department of Neurology, Istanbul, TURKEY</aff>
<aff id="aff2-1550059412459330"><label>2</label>Istanbul University, Institute for Experimental Medicine, Department of Neuroscience, Istanbul, TURKEY</aff>
<author-notes>
<corresp id="corresp1-1550059412459330">Erdem Tüzün, Department of Neurology, Istanbul University, Istanbul Faculty of Medicine, 34390, Çapa, Istanbul, TURKEY. Email: <email>drerdem@yahoo.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>7</month>
<year>2013</year>
</pub-date>
<volume>44</volume>
<issue>3</issue>
<fpage>232</fpage>
<lpage>236</lpage>
<history>
<date date-type="received">
<day>24</day>
<month>6</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>4</day>
<month>8</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© EEG and Clinical Neuroscience Society (ECNS) 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="society">EEG and Clinical Neuroscience Society</copyright-holder>
</permissions>
<abstract>
<p>Autoimmune encephalitis associated with glutamic acid decarboxylase antibodies (GAD-Ab) often presents with treatment-resistant partial seizures, as well as other central nervous system symptoms. In contrast to several other well-characterized autoantibodies, GAD-Ab has very rarely been associated with status epilepticus. We report a 63-year-old woman initially admitted with somnolence and psychiatric findings. The EEG findings, of generalized and rhythmical slow spike-wave activity over the posterior regions of both hemispheres, together with the clinical deterioration in responsiveness, led to the diagnosis of non-convulsive status epilepticus. Investigation of a broad panel of autoantibodies, revealed only increased serum GAD-Ab levels. Following methylprednisolone and intravenous immunoglobulin treatments, the patient's neurological symptoms improved, EEG findings disappeared and GAD-Ab levels significantly decreased. GAD-Ab should be added to the list of anti-neuronal antibodies associated with non-convulsive status epilepticus. Disappearance of clinical findings and seroreversion after immunotherapy suggest that GAD-Ab might be involved in seizure pathogenesis.  </p>
</abstract>
<kwd-group>
<kwd>glutamic acid decarboxylase</kwd>
<kwd>non-convulsive status</kwd>
<kwd>epilepsy</kwd>
<kwd>antibody</kwd>
<kwd>autoimmunity.</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1550059412459330">
<title>Introduction</title>
<p>Glutamic acid decarboxylase (GAD) is a key enzyme required for the conversion of glutamic acid into gamma aminobutyric acid (GABA). Antibodies directed against GAD (GAD-Ab) have been implicated in the pathogenesis of type 1 diabetes mellitus, and neurological diseases such as stiff-person syndrome, cerebellar ataxia and limbic encephalitis.<sup>
<xref ref-type="bibr" rid="bibr1-1550059412459330">1</xref>
<xref ref-type="bibr" rid="bibr2-1550059412459330"/>-<xref ref-type="bibr" rid="bibr3-1550059412459330">3</xref>
</sup> More recently, GAD autoimmunity was associated with treatment-resistant epilepsy, particularly with partial seizures.<sup>
<xref ref-type="bibr" rid="bibr4-1550059412459330">4</xref>
<xref ref-type="bibr" rid="bibr5-1550059412459330"/>-<xref ref-type="bibr" rid="bibr6-1550059412459330">6</xref>
</sup> Alternatively, GAD-Ab have been far more rarely reported in association with epileptic status.<sup>
<xref ref-type="bibr" rid="bibr7-1550059412459330">7</xref>
<xref ref-type="bibr" rid="bibr8-1550059412459330"/>-<xref ref-type="bibr" rid="bibr9-1550059412459330">9</xref>
</sup>
</p>
<p>We report a limbic encephalitis patient, presenting with non-convulsive status epilepticus and elevated serum GAD-Ab levels. Significant and prompt response of the patient to first-line immunotherapies, and a sharp decline in GAD-Ab levels in parallel with clinical amelioration, suggest that GAD-Ab might have epileptogenic activity.</p>
</sec>
<sec id="section2-1550059412459330">
<title>Case Report</title>
<p>A 63-year-old woman was admitted with a 5-month history of slowly progressing social withdrawal, recurrent episodes of purposeless crying, insomnia, visual hallucinations and paranoid delusions. In the last few days, she had also developed drowsiness, agitation and incoherent talking. She had hypertension and type II diabetes mellitus, but no prior history of psychosis or any other psychiatric disorder. Neurological examination revealed somnolence, disorientation to time and place, dysarthria, and mild generalized rigidity. Cranial MRI examination was normal.</p>
<p>The first EEG examination performed during admission, showed diffusely slowed background activity with 5-6 Hz theta rhythms (<xref ref-type="fig" rid="fig1-1550059412459330">Figure 1</xref>). Ten days after admission, the patient showed clinical deterioration in responsiveness, increased agitation and paranoid delusions, prompting a repeat EEG examination, which revealed generalized, nearly continuous 1.5-2 Hz rhythmical spike-waveactivity, predominating over the posterior regions of both hemispheres (<xref ref-type="fig" rid="fig2-1550059412459330">Figure 2A</xref>). This activity led to the diagnosis of non-convulsive status epilepticus. After administration of intravenous diazepam, EEG seizure activity stopped temporarily. However, under gradually increased dosages of oral valproate (maximum 2000 mg/day) and phenytoin (maximum 200 mg/day) the clinical symptoms did not improve, and control EEGs performed in the following days showed that non-convulsive status epilepticus activity continued, and did not respond to antiepileptic treatment (<xref ref-type="fig" rid="fig2-1550059412459330">Figure 2B</xref>). </p>
<fig id="fig1-1550059412459330" position="float">
<label>Figure 1.</label>
<caption>
<p>The first EEG examination showing diffusely slowed background activity with 5-6 Hz theta rhythms. </p>
</caption>
<graphic xlink:href="10.1177_1550059412459330-fig1.tif"/>
</fig>
<fig id="fig2-1550059412459330" position="float">
<label>Figure 2.</label>
<caption>
<p>Generalized, nearly continuous 1.5-2 Hz rhythmical spike-wave activity predominating over the posterior regions of the two hemispheres (A). EEG controls showed that non-convulsive status epilepticus activity continued and did not respond to the antiepileptic treatments (B).</p>
</caption>
<graphic xlink:href="10.1177_1550059412459330-fig2.tif"/>
</fig>
<p>Complete blood count, blood biochemistry, sedimentation rate and thyroid function tests were normal. Cerebrospinal fluid (CSF) examination revealed normal cell count, protein and glucose concentration values and type 3 pattern oligoclonal bands, suggesting intrathecal IgG synthesis. A comprehensive screening for infectious (herpes simplex virus and human immunodeficiency virus) and systemic autoimmune disorders (anti-nuclear antibody, thyroid antibodies, anti-neutrophil cytoplasmic antibodies, cardiolipin antibodies, anti-DNA antibody and rheumatoid factor) proved negative. The patient’s serum was also negative for Hu, Yo, Ri, Ma2, CV2, amphiphysin, N-methyl-D-aspartate receptor (NMDAR), leucine-rich glioma inactivated 1 (LGI1), contactin associated protein-like 2 (CASPR2), alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR), gamma-aminobutyric acid B receptor (GABA<sub>B</sub>R) antibodies (all measured by relevant Euroimmun kits, Luebeck, Germany), and voltage-gated potassium channel (VGKC) antibodies (measured by radioimmunoassay, as previously reported).<sup>
<xref ref-type="bibr" rid="bibr10-1550059412459330">10</xref>
</sup> By contrast, the patient had high serum GAD-Ab levels (2127 U/ml, normal value &lt;10 U/ml), as measured by an ELISA kit per manufacturer’s instructions (Euroimmun). Total body CT scan failed to show a mass lesion. Mammography, routine gynecological examination, pap-smear test, and serum levels of cancer markers were all normal.</p>
<p>Psychiatric findings, confusion, EEG seizure activity, high serum GAD-Ab levels, oligoclonal CSF bands, and exclusion of other etiological factors associated with limbic symptoms, led to the diagnosis of autoimmune limbic encephalitis, and immunotherapy was started. The patient showed no response to pulse intravenous methylprednisolone treatment (5x1gr/day). However, a few days after intravenous immunoglobulin (IVIg) treatment (2g/kg in 2 days) that was commenced right after steroid treatment, her level of consciousness and EEG findings started to improve markedly. (<xref ref-type="fig" rid="fig3-1550059412459330">Figure 3</xref>). Under monthly IVIg treatment, the patient’s symptoms, neurological examination and EEG findings completely returned to normal within 3 months. A repeat GAD-Ab assay performed at that time revealed significantly reduced serum antibody levels (32 U/ml). </p>
<fig id="fig3-1550059412459330" position="float">
<label>Figure 3.</label>
<caption>
<p>After immunotherapy, the EEG findings were improved markedly showing again 5-6 Hz theta rhythms and rare spike-waves over the central regions.</p>
</caption>
<graphic xlink:href="10.1177_1550059412459330-fig3.tif"/>
</fig>
</sec>
<sec id="section3-1550059412459330">
<title>Discussion</title>
<p>High titres of GAD-Ab have been associated with limbic encephalitis and epilepsy. The great majority of these patients had treatment-resistant partial (mostly temporal lobe) seizures or partial seizures that were often the predominant feature of the clinical syndrome.<sup>
<xref ref-type="bibr" rid="bibr4-1550059412459330">4</xref>
<xref ref-type="bibr" rid="bibr5-1550059412459330"/>–<xref ref-type="bibr" rid="bibr6-1550059412459330">6</xref>
</sup> Only a small number of reported epileptic status cases are associated with GAD-Ab. These cases always had convulsive seizures, and mostly displayed a rare type of localization-related epilepsy, epilepsia partialis continua.<sup>
<xref ref-type="bibr" rid="bibr7-1550059412459330">7</xref>
<xref ref-type="bibr" rid="bibr8-1550059412459330"/>–<xref ref-type="bibr" rid="bibr9-1550059412459330">9</xref>
</sup> In contrast with previous cases, our patient never displayed convulsive seizures, and also did not have any clinical or EEG evidence of partial seizures. Nevertheless, the possibility that the psychological and behavioral symptoms encountered by the patient prior to her admission were due to partial seizures, cannot be entirely ruled out. To our knowledge, our patient represents the first case of GAD-Ab positive non-convulsive status epilepticus, implying that GAD-Ab should be added to the panel of other antibodies associated with non-convulsive status epilepticus, such as Hu-Ab and NMDAR-Ab.<sup>
<xref ref-type="bibr" rid="bibr11-1550059412459330">11</xref>,<xref ref-type="bibr" rid="bibr12-1550059412459330">12</xref>
</sup>
</p>
<p>In resemblance to anti-neuronal antibodies directed against ion channels located at neuronal membranes,<sup>
<xref ref-type="bibr" rid="bibr4-1550059412459330">4</xref>
</sup> GAD-Ab appear to exert epileptogenic activity, presumably by decreasing the conversion of GAD into GABA, and thus increasing the dominance of excitatory neurotransmitters.<sup>
<xref ref-type="bibr" rid="bibr13-1550059412459330">13</xref>
</sup> However, GAD-Ab associated encephalitis differs from ion channel antibody associated encephalitis in that; (i) target antigen, GAD, is an intracellular protein and thus is not within the reach of circulating antibodies, (ii) GAD-Ab positive patients often do not respond to first-line antibody depleting treatment methods,<sup>
<xref ref-type="bibr" rid="bibr4-1550059412459330">4</xref>,<xref ref-type="bibr" rid="bibr6-1550059412459330">6</xref>,<xref ref-type="bibr" rid="bibr9-1550059412459330">9</xref>
</sup> (iii) in many GAD-Ab positive patients, clinical symptoms appear to be loosely correlated with antibody levels<sup>
<xref ref-type="bibr" rid="bibr4-1550059412459330">4</xref>
</sup>, and (iv) GAD-Ab positive patients often display additional antibodies to ion channels such as NMDAR and VGKC.<sup>
<xref ref-type="bibr" rid="bibr3-1550059412459330">3</xref>,<xref ref-type="bibr" rid="bibr4-1550059412459330">4</xref>
</sup> Moreover, experimental epilepsy studies suggest that neuronal GAD expression is profoundly increased after seizures.<sup>
<xref ref-type="bibr" rid="bibr14-1550059412459330">14</xref>
</sup> These findings suggest that, in epilepsy patients, GAD autoimmunity might not have a genuine pathogenic action, and might rather be a bystander effect generated by seizure-induced increases in GAD expression, blood-brain barrier permeability, and widespread neuronal destruction. Then again, as seen in our patient’s clinical course, some of the GAD-Ab positive patients might be promptly treated by first-line immunotherapies, and clinical amelioration might occasionally be coupled with a significant decline in GAD-Ab levels,<sup>
<xref ref-type="bibr" rid="bibr7-1550059412459330">7</xref>,<xref ref-type="bibr" rid="bibr8-1550059412459330">8</xref>,<xref ref-type="bibr" rid="bibr15-1550059412459330">15</xref>
</sup> suggesting that in a subgroup of GAD-Ab associated limbic encephalitis/epilepsy patients, GAD-Ab might be directly involved in seizure pathogenesis. </p>
<p>The features of our patient show a striking resemblance to those of previously reported GAD-Ab associated limbic encephalitis cases.<sup>
<xref ref-type="bibr" rid="bibr6-1550059412459330">6</xref>
</sup> High-titer GAD-Ab levels (&gt;1000 U/ml), CSF oligoclonal bands, and lack of response to pulse steroid treatment, appear to be the most crucial and defining features of GAD-Ab encephalitis.<sup>
<xref ref-type="bibr" rid="bibr6-1550059412459330">6</xref>
</sup> In this context, our case underlines the significance of CSF oligoclonal bands in the diagnosis of limbic encephalitis, especially when CSF cell count and protein parameters are normal, and there is no imaging evidence of medial temporal lobe involvement. Also, as observed in our case, in non-steroid responsive GAD-Ab encephalitis cases, IVIg and plausibly plasma exchange, should be considered before starting more toxic immunosuppressive agents, such as cyclophosphamide.</p>
<p>In conclusion, the features of our case suggest that (i) GAD-Ab encephalitis should be considered in the differential diagnosis of non-convulsive status epilepticus, (ii) GAD-Ab might have a pathogenic role in seizure generation at least in some patients, (iii) CSF oligoclonal bands might indicate GAD autoimmunity in encephalitis cases with no additional abnormal laboratory findings, and (iv) IVIg might be considered as a primary treatment of choice in treatment-resistant GAD-Ab encephalitis patients. </p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="other" id="fn3-1550059412459330">
<p>Full-color figures are available online at <ext-link ext-link-type="uri" xlink:href="http://eeg.sagepub.com">http://eeg.sagepub.com</ext-link></p>
</fn>
<fn fn-type="conflict" id="fn1-1550059412459330">
<label>Declaration of Conflicting Interests</label>
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-1550059412459330">
<label>Funding</label>
<p>The authors received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1550059412459330">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>McKeon</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>McEvoy</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Matsumoto</surname>
<given-names>JY</given-names>
</name>
<name>
<surname>Lennon</surname>
<given-names>VA</given-names>
</name>
<name>
<surname>Ahlskog</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Pittock</surname>
<given-names>SJ</given-names>
</name>
</person-group>. <article-title>Stiff-man syndrome and variants: clinical course, treatments, and outcomes</article-title>. <source>Arch Neurol</source> <year>2012</year>; <volume>69</volume>:<fpage>230</fpage>–<lpage>238</lpage>. </citation>
</ref>
<ref id="bibr2-1550059412459330">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pittock</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Yoshikawa</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ahlskog</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Tisch</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Benarroch</surname>
<given-names>EE</given-names>
</name>
<name>
<surname>Kryzer</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Lennon</surname>
<given-names>VA</given-names>
</name>
</person-group>. <article-title>Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction</article-title>. <source>Mayo Clin Proc</source> <year>2006</year>; <volume>81</volume>:<fpage>1207</fpage>–<lpage>1214</lpage>.</citation>
</ref>
<ref id="bibr3-1550059412459330">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Saiz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Blanco</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Sabater</surname>
<given-names>L</given-names>
</name>
<name>
<surname>González</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bataller</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Casamitjana</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association</article-title>. <source>Brain</source> <year>2008</year>; <volume>131</volume>:<fpage>2553</fpage>–<lpage>2563</lpage>.</citation>
</ref>
<ref id="bibr4-1550059412459330">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vincent</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bien</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Irani</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Waters</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Autoantibodies associated with diseases of the CNS: new developments and future challenges</article-title>. <source>Lancet Neurol</source> <year>2011</year>; <volume>10</volume>:<fpage>759</fpage>–<lpage>772</lpage>.</citation>
</ref>
<ref id="bibr5-1550059412459330">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Falip</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Carreño</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Miró</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Saiz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Villanueva</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Quílez</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Prevalence and immunological spectrum of temporal lobe epilepsy with glutamic acid decarboxylase antibodies</article-title>. <source>Eur J Neurol</source> <year>2012</year>; <volume>19</volume>:<fpage>827</fpage>–<lpage>833</lpage>. </citation>
</ref>
<ref id="bibr6-1550059412459330">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malter</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Helmstaedter</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Urbach</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Vincent</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bien</surname>
<given-names>CG</given-names>
</name>
</person-group>. <article-title>Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis</article-title>. <source>Ann Neurol</source> <year>2010</year>; <volume>67</volume>:<fpage>470</fpage>–<lpage>478</lpage>.</citation>
</ref>
<ref id="bibr7-1550059412459330">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olson</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Olson</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Sandborg</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Alexander</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Buckingham</surname>
<given-names>B</given-names>
</name>
</person-group>. <article-title>Type 1 diabetes mellitus and epilepsia partialis continua in a 6-year-old boy with elevated anti-GAD65 antibodies</article-title>. <source>Pediatrics</source> <year>2002</year>; <volume>109</volume>:<fpage>E50</fpage>.</citation>
</ref>
<ref id="bibr8-1550059412459330">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baglietto</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Mancardi</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Giannattasio</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Minuto</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Rossi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Capovilla</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Epilepsia partialis continua in type 1 diabetes: evolution into epileptic encephalopathy with continuous spike-waves during slow sleep</article-title>. <source>Neurol Sci</source> <year>2009</year>; <volume>30</volume>:<fpage>509</fpage>–<lpage>512</lpage>.</citation>
</ref>
<ref id="bibr9-1550059412459330">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kanter</surname>
<given-names>IC</given-names>
</name>
<name>
<surname>Huttner</surname>
<given-names>HB</given-names>
</name>
<name>
<surname>Staykov</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Biermann</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Struffert</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kerling</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Cyclophosphamide for anti-GAD antibody-positive refractory status epilepticus</article-title>. <source>Epilepsia</source> <year>2008</year>; <volume>49</volume>:<fpage>914</fpage>–<lpage>920</lpage>.</citation>
</ref>
<ref id="bibr10-1550059412459330">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vincent</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Buckley</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Schott</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Dewar</surname>
<given-names>BK</given-names>
</name>
<name>
<surname>Detert</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis</article-title>. <source>Brain</source> <year>2004</year>; <volume>127</volume>:<fpage>701</fpage>–<lpage>712</lpage>.</citation>
</ref>
<ref id="bibr11-1550059412459330">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Espay</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Sarpel</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Anti-Hu-associated paraneoplastic limbic encephalitis presenting as rapidly progressive non-convulsive status epilepticus</article-title>. <source>J Neurol Sci</source> <year>2006</year>; <volume>246</volume>:<fpage>149</fpage>–<lpage>152</lpage>.</citation>
</ref>
<ref id="bibr12-1550059412459330">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldberg</surname>
<given-names>EM</given-names>
</name>
<name>
<surname>Taub</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Kessler</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>Abend</surname>
<given-names>NS</given-names>
</name>
</person-group>. <article-title>Anti-NMDA receptor encephalitis presenting with focal non-convulsive status epilepticus in a child</article-title>. <source>Neuropediatrics</source> <year>2011</year>; <volume>42</volume>:<fpage>188</fpage>–<lpage>190</lpage>.</citation>
</ref>
<ref id="bibr13-1550059412459330">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mitoma</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Ishida</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Yamakuni</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Mizusawa</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Presynaptic impairment of cerebellar inhibitory synapses by an autoantibody to glutamate decarboxylase</article-title>. <source>J Neurol Sci</source> <year>2000</year>; <volume>175</volume>:<fpage>40</fpage>–<lpage>44</lpage>.</citation>
</ref>
<ref id="bibr14-1550059412459330">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sperk</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Wieselthaler-Hölzl</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pirker</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tasan</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Strasser</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Drexel</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Glutamate decarboxylase 67 is expressed in hippocampal mossy fibers of temporal lobe epilepsy patients</article-title>. <source>Hippocampus</source> <year>2012</year>; <volume>22</volume>:<fpage>590</fpage>–<lpage>603</lpage>.</citation>
</ref>
<ref id="bibr15-1550059412459330">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lenti</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bognetti</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bonfanti</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bonifacio</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Meschi</surname>
<given-names>F</given-names>
</name>
</person-group>. <article-title>Myoclonic encephalopathy and diabetes mellitus in a boy</article-title>. <source>Dev Med Child Neurol</source> <year>1999</year>; <volume>41</volume>:<fpage>489</fpage>–<lpage>490</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>